1 / 59

Fig 2: Da Devare SG, J Med Virol 2007

Fig 2: Da Devare SG, J Med Virol 2007. Fig 2: Da Devare SG, J Med Virol 2007. Fig 2: Da Devare SG, J Med Virol 2007. Da Nick et al, J Med Virol 2007. Reduction in New HIV Diagnoses in BC: Testing, HAART, and Community VL. ≥ 50,000. 3500-9999. 500-3499. 12,000. 1400. < 500.

haviva-ross
Download Presentation

Fig 2: Da Devare SG, J Med Virol 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fig 2: Da Devare SG, J Med Virol 2007 Fig 2: Da Devare SG, J Med Virol 2007 Fig 2: Da Devare SG, J Med Virol 2007

  2. Da Nick et al, J Med Virol 2007

  3. Reduction in New HIV Diagnoses in BC: Testing, HAART, and Community VL ≥ 50,000 3500-9999 500-3499 12,000 1400 < 500 HIV-1 RNA, copies/mL Censored at the time of death or move 10,000 1200 8000 1000 New HIV+diagnoses (all) 800 New HIV+ Diagnoses (n) 6000 Patients (n) 600 10,000-49,999 4000 400 2000 200 0 0 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 • Period of declining new HIV diagnoses in BC coincident with increased HIV testing rates, increased uptake of antiretroviral therapy, and decrease in community viral load (1996-2008) • Decline in new HIV diagnoses despite increases in syphilis, gonorrhea, chlamydia Montaner J, et al. CROI 2010. Abstract 88LB. Reproduced with permission.

  4. The decline of HIV DNA values during an effective therapy was directly related to baseline HIV DNA and HIV RNA values at baseline, to the increase in the number of CD4 cells to the achievement of a HIV RNA load <2.5 copies/ml. Undetectable HIV DNA cellular load was achieved by 21.6% of patients at the follow-up time point and significantly correlated with lower baseline cellular HIV DNA values and being in the primary stage of infection when therapy started. In conclusion, early treatment facilitated the achievement of undetectable levels of plasma viraemia and cellular HIV DNA and a better recovery of CD4 lymphocytes. HIV DNA level before and during highly active antiretroviral therapy may be used as a new tool for monitoring treatment efficacy Parisi et al, J Clin Microb 2012

  5. 296 soggetti studiati alla diagnosi per resistenze nell’anno 2009 in Veneto

  6. 303 soggetti studiati alla diagnosi per resistenze nell’anno 2010 in Veneto

  7. 245 soggetti studiati alla diagnosi per resistenze nell’anno 2011 in Veneto

More Related